Michael M Shi

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell l...

Surufatinib in gevorderd neuroendocrine tumours: Final totale overleving from two randomised, double-blind, placebo-c...